

Therapeutic interventions against accumulation of Advanced Glycation End products (AGEs)

Originally published as *Glycative Stress Research* 2017; 4 (2): 132-143
Updated May 2021

Abstract

Advanced Glycation End products (AGEs) are formed in non-enzymatic glycation reactions between reducing sugars and proteins, lipids or nucleic acids. AGEs build up in the body during aging and are involved in the development of a host of pathologies such as diabetes, atherosclerosis, cardiovascular disease, renal disease and Alzheimer's disease. Since AGE levels are a good independent predictor of disease progression and mortality, AGE measurements can provide new information to the current prognosis and treatment options. Moreover, research regarding interventions to reduce AGE accumulation has been of major interest the latest years. Given that the evidence for the role of glycation in tissue damage and in the progression of chronic disease is now overwhelming, there is a real and urgent need for an effective anti-glycation intervention.

This review examines the anti-glycation interventions that have been studied in clinical trials or in *in vivo* studies and are currently available for human use. Interventions can be aimed at different stages of the AGE formation pathway and depend on different mechanisms, among which antioxidant ability, scavenging of reactive carbonyl species (RCS) or breaking AGE-induced crosslinks. Pharmaceutical options show promising results, even though in some cases their clinical relevance is doubtful so far due to safety concerns. For individuals with high AGE levels but no current clinical symptoms, lifestyle interventions such as a low AGE diet and physical exercise might be more effective. Nutraceuticals, derived from food sources and available as dietary supplements, have mostly been investigated in pre-clinical studies and show positive effects on diabetic complications such as nephropathy and retinopathy.

Keywords: advanced glycation end products (AGEs), diabetic complications, therapy, lifestyle interventions

Introduction on Advanced Glycation End products

Advanced glycation end products (AGEs) are a diverse set of compounds that accumulate in tissues during normal ageing and contribute to a range of diseases such as diabetes mellitus and its complications, neurodegeneration and inflammation.¹ AGEs are generated when sugars react with proteins, lipids or nucleic acids in a non-enzymatic way. This glycation process is described as the Maillard reaction and is known for the browning of foods. This reaction is characterized by a few steps with intermediate products to eventually form AGEs. When the carbonyl group of reducing sugars react with the amino-terminal group of proteins, an unstable Schiff base is formed in a reversible process. During rearrangements, the more stable Amadori product is produced, e.g. the glycated haemoglobin HbA1c. When further reactions including rearrangements, oxidation and dehydration take place, AGEs will be produced.² During these rearrangements highly reactive intermediate α -dicarbonyls, also known as reactive carbonyl species (RCS), accumulate and cause carbonyl stress. Examples of these products are 3-deoxyglucosone (3-DG) and methylglyoxal (MGO).³ RCS and AGE formation can also occur by glycooxidation or lipid peroxidation.⁴

Increasingly, studies are corroborating the causal relationship between MGO-derived AGEs and age-related tissue dysfunction, unveiling a previously underestimated role of dicarbonyl stress in unhealthy aging¹²³. MGO-derived AGEs further appear to induce mitochondrial dysfunction and reduced energy availability.




Fig 1. During the traditional Maillard reaction reducing sugars react with the amino group of proteins to form intermediate products Schiff bases and Amadori products and eventually AGEs. More recently it appeared AGEs can be formed through other pathways such as glycooxidation and lipid peroxidation where reactive carbonyl species (RCS) are generated that covalently bind to proteins. (CML- carboxy-methyl-lysine; CEL- carboxy-ethyl-lysine; GO: glyoxal; MGO- methylglyoxal; 3-DG- 3-deoxyglucosone)

Under physiological circumstances, the endogenous AGE production will take weeks or years and long-lived proteins such as collagen are the major target. Under stress conditions such as hyperglycemia or oxidative stress this reaction accelerates and can also affect short-lived substrates (e.g. enzymes and hormones), inducing structural changes.⁵

AGEs can also come from exogenous sources such as food of which 10% of the AGEs is estimated to be absorbed in the gut.⁶ Animal-derived foods, high in fat and protein, consist of high AGE levels. In contrast, food that is enriched with carbohydrates, such as whole grains, vegetables and fruit, are generally low in AGEs. Since high temperatures can accelerate AGE formation, food processing by heating can contribute to the accumulation of AGEs in the body.⁷ Furthermore, smoking is an important exogenous source of AGEs.⁸

Role of AGEs in health and disease

The formation of AGEs and accumulation in the body are natural processes during ageing. Aging is explained as a multifactorial process leading to a gradual decline in physiological functions, affecting all tissues in the body.⁹ High rates of AGE accumulation in the skin have been shown to correlate with aging¹⁰ and excessive AGE accumulation can accelerate the aging process. The amount of AGEs is based on the rate of formation, determined by ROS and reducing sugars, and the rate of clearance, determined by the activity of the glyoxalase system, where glyoxalase I (Glo I) is able to detoxify reactive carbonyl compounds.¹¹ Aging can cause an imbalance in this system, since ROS is present in a larger extent while Glo I activity is decreased.¹ Furthermore, AGE accumulation is aggravated in some chronic diseases as well, such as cardiovascular disease, diabetes mellitus, renal failure and Alzheimers disease.² AGEs can damage cells and tissues through several mechanisms and thereby contribute to aging or disease.

First, AGEs can bind to certain receptors (RAGE; receptor for Advanced Glycation End products) on different cells. This induces several signaling cascades, among which activation of MAP kinases and the JAK/STAT pathway.^{14,15} Many of these signaling pathways lead to the activation of transcription factors such as NFκB, which induces a diverse set of target genes. Pro-inflammatory genes (e.g. TNF-α, IL-1 and IL-6),

adhesion molecules (e.g. VCAM-1) and vasoconstrictors are activated.^{1,14} In addition, reactive oxygen species (ROS) are generated by activation of NADPH oxidases and then stimulate the further formation of AGEs.¹⁵ Oxidative stress and inflammation can in their turn elicit tissue damage and lead to accelerated aging.⁹

Besides a receptor-mediated response, AGEs are responsible for alterations in protein function. Glycation of (intracellular) proteins can alter their structure and lead to impaired function of growth factors, enzymes and transcription factors, contributing to impaired cell function.⁵ Furthermore, AGEs stimulate the formation of crosslinks between (intracellular) proteins, and can trap (lipo)proteins.¹² Accumulation of AGEs in the extracellular matrix (ECM) can result in crosslinking of collagen molecules leading to stiffness and decreased elasticity of tissues.¹⁶ Particularly tissues rich in ECM and long-lived proteins such as skin, skeletal muscles, tendons, heart and lens are targeted by this stiffening and is associated with aging.¹⁷ Under pathological conditions the consequences of crosslinking by AGEs include thickening of the capillary basement membrane, rigid vessels and development of atherosclerosis and glomerular sclerosis.¹⁸

In patients suffering from diabetes or renal disease, AGEs accumulate more rapidly due to hyperglycaemia, oxidative stress or impaired renal clearance. AGEs then contribute to the progression of these diseases and complications such as diabetic neuropathy, nephropathy and the formation of cataract. Atherosclerosis is the major cause of death in diabetic patients¹⁹ and is characterized by cross-linking of extracellular matrix proteins in the vessel wall by AGE accumulation, thereby trapping plasma proteins.²⁰ Moreover, AGEs in the vessel wall interfere with the nitric oxide (NO)-mediated relaxation ability of the endothelium.²¹

NF- κ B signalling and ROS induce apoptosis of pericytes and endothelial cells,²² contributing to diabetic retinopathy. This is enhanced by hyperpermeability of capillaries, resulting in vascular leakage.²³ In addition, the thickening of the capillary basement membranes by increased synthesis of collagen and other matrix molecules is a mechanism by which retinopathy is strengthened.²⁴ The same mechanisms play a role in the pathophysiology of diabetic nephropathy. Apoptosis of mesangial cells²⁵ and the thickening of the glomerular basement membrane is partly responsible for altered filtration, albuminuria and eventually renal failure.²




Fig. 2 AGEs contribute to aging and disease by different mechanisms. Glycation of proteins alters their structure and function, leading to impaired cell function. AGE-RAGE interaction activates NF κ B, inducing several cellular responses, such as apoptosis, production of pro-inflammatory cytokines and ROS. Finally, AGEs form crosslinks between collagen and other proteins, leading to tissue stiffening. These are key processes in many diabetic complications, such as atherosclerosis, diabetic nephropathy and diabetic neuropathy.

AGE accumulation represents 'glycaemic memory': the phenomenon that explains the sustained beneficial effects long after a period of intensive glycaemic control, as well as the prolonged harmful effects after hyperglycaemia.^{26,27} Together with their role in diabetic complications, measuring AGEs is emerging as a tool to predict the odds of developing complications and detect patients at risk. The AGE Reader (Diagnoptics, Groningen, the Netherlands) provides a non-invasive, quick and reproducible way for the AGE-related skin autofluorescence (SAF). Skin AGE levels proved to be an independent predictor of microvascular complications in type 2 diabetes.²⁸ Furthermore, skin autofluorescence is, except for age, the best predictor for (cardiovascular) mortality and provides additional information to conventional CV risk assessment engines.²⁹

Interventions to reduce AGEs

Since AGEs have shown to play an important role in aging and the development and progression of many chronic diseases, they are an excellent target for new therapies. To diminish the harmful effect of AGEs on cellular and tissue functioning, interventions are proposed that either avoid the further formation or accumulation of AGEs or remove the AGEs that are already formed. This review gives an overview of existing and potential interventions that can inhibit AGEs now or in the near future, which are classified in pharmacologic, lifestyle and nutraceutical interventions.

Pharmacologic interventions

Researchers have been ambitious to find substances with AGE-reducing properties. Compounds that have been studied extensively are Aminoguanidine (AG) and Alagebrium (ALT-711).

Aminoguanidine (AG) is a small molecule that reacts with dicarbonyl compounds (e.g. MG and 3-DG) and Amadori intermediates to inhibit the formation of AGEs.³⁰ The first clinical trial (ACTION) was performed to evaluate the effect of AG on the further development of diabetic nephropathy. A large cohort of 690 patients with T1DM and known nephro- and retinopathy participated and were treated for 2-4 years with AG. Overall, a significant reduction of diabetes complications was observed. AG administration reduced the 24-hour proteinuria and could prevent the decrease in glomerular filtration rate. However, the inhibition of AGE formation by AG showed no effect on serum creatinine.³¹ A second trial, involving AG therapy in T2DM patients, was early terminated due to undesirable side effects such as abnormalities in liver function, gastrointestinal problems and anemia.³²

Alagebrium (ALT-711) has the ability to break crosslinks of Maillard reaction products and demonstrated positive effects on atherosclerosis and diabetic nephropathy in vivo. Clinical studies that have been performed mostly investigated the use of Alagebrium in patients with hypertension or heart failure. Two studies that examined hypertensive patients treated with Alagebrium for a relative short period (8-10 weeks)^{33,34}, showed some beneficial effects on several cardiovascular variables, such as an increase in arterial compliance and a decrease of arterial pulse pressure.³³ Furthermore endothelial function was improved and the therapy might reduce arterial remodelling. Nevertheless, the same study reported no changes in cardiac output, blood pressure and systolic or diastolic function and other cardiovascular variables.³⁴ In a study where 23 patients with diastolic heart failure were treated for four months ambiguous results were found. Although diastolic function and left ventricular mass were improved, no change in VO₂ max, blood pressure or aortic distensibility were found.³⁵ Another study observing 102 heart failure patients after 9 months of treatment did not show positive results and could not find an improvement of diastolic and systolic function, AGE accumulation or New York Heart Association (NYHA) classification.³⁶ Similarly, no convincing results on hemodynamics or exercise capacity could be detected after 1 year of treatment in healthy individuals.^{37,38} Although Alagebrium has not been licensed as a drug, its safety profile and effectiveness concerning several cardiovascular variables are still promising.

Azeliragon is a RAGE inhibitor and has been tested in clinical trials to diminish Alzheimer's Disease (AD). RAGE is not only a receptor for AGEs, but can bind amyloid β as well. In AD, RAGE expression is

upregulated in the brain and contributes to inflammation, oxidative stress and neurodegeneration.³⁹ RAGE antagonist Azeliragon (also known as TTP488 or PF-04494700) was administered to 399 patients for 18 months to inhibit the interaction between RAGE and amyloid β and block signal transduction.⁴⁰ This also might be interesting to counteract the detrimental effects of AGEs through its receptor. A low dose was suggested to have a decreased decline on the Alzheimer's Disease Assessment Scale–cognitive (ADAS-cog), a test that determines parameters as memory, reasoning, language and orientation.⁴¹ Nevertheless, there was no significant difference in other clinical markers and the study was terminated early.⁴⁰ The drug was developed earlier for diabetic neuropathy but this study was discontinued as well.

SGLT2 inhibitors are another interesting group of glucose-lowering medication. SGLT2 re-absorbs glucose filtered by the kidney and when inhibited reduces blood glucose in an insulin independent manner¹²⁴. In a Japanese study administration of luseogliflozin, an SGLT2 inhibitor, appears to be able to reduce tissue AGE levels. 197 patients were divided into two groups: patients with/without diabetes. There was no significant change in SAF in the non-diabetes group after 6 months, while there was a significant reduction after 6 months from baseline in the diabetes group of -0.15 in SAF ($p < 0.001$) (Anti-Aging Medicine 2020; 16(1): 89-95).

Besides pharmaceuticals that specifically target AGEs, there is another subset of generic drugs, initially developed to decrease blood pressure or cholesterol, but happen to have an effect on AGEs as well. Several small studies on metformin, glucose-lowering medication, showed some beneficial effects on glycation measures, such as a decrease of MG⁴² and lower AGEs and oxidative stress in patients with type 2 diabetes.⁴³ Not all studies were able to find additional effects, therefore the AGE-inhibition capacity of metformin might be attributed merely to improved glycaemic control instead of dicarbonyl quenching.

Lipid-lowering medication might inhibit AGE formation as well due to anti-oxidative properties, which partly reduces lipid peroxidation. Atorvastatin showed a decrease in serum AGEs in non-alcoholic steatohepatitis (NASH) patients with dyslipidemia after 12 months of treatment.⁴⁴ Serum AGEs were also reduced in patients with non-diabetic chronic kidney disease and dyslipidemia after one year of atorvastatin treatment.⁴⁵ This effect was also observed in diabetic patients that received cerivastatin for three months.⁴⁶ In addition to the decrease in serum AGEs, simvastatin showed a decrease of RAGE expression in carotid artery plaques, by inhibition of AGE formation.⁴⁷

Finally, blood pressure-regulating medication also has a potential effect on AGEs. Until now, only one small study on ACE-inhibitors has evaluated the effect on AGE formation. Ramipril treatment for two months decreased fluorescent AGEs, but not non-fluorescent CML, alongside reduced blood pressure and proteinuria.⁴⁸ Furthermore, Angiotensin Receptor blockers have shown in several small studies that they possess AGE-reducing effects. One year of valsartan treatment decreased serum AGEs, but did not affect other metabolic and oxidative markers in diabetic hypertensive patients.⁴⁹ Candesartan administration to diabetic patients for three months decreased urinary AGEs⁵⁰ and in addition slightly improved creatinine clearance in diabetic kidney disease patients.⁵¹ In contrast, a larger randomised controlled trial with a longer follow-up period could not detect a treatment effect of irbestartan on AGEs in type 2 diabetic subjects with microalbuminuria.⁵²

Lifestyle interventions

Pharmaceutical interventions against AGEs are not approved yet to be clinically used. For individuals that have high AGE levels but no clinical signs of disease yet, non-medical interventions such as adopting a healthy lifestyle might be a more effective approach to prevent further AGE accumulation and increase healthspan (*i.e.* the disease-free time of life).

Low AGE diet

Since the composition and especially the preparation of food largely determine the amount of exogenous

AGE intake, a diet low in AGEs can reduce the absorbed AGEs from the gut. Several studies on a low AGE diet have been completed, using different study populations (healthy and obese subjects as well as patients with diabetes and renal failure). The duration of the low AGE diet differed between studies, but were all between 1 and 4 months. The decrease of AGEs in the diet was between 30 and 60%, which was generally due to differences in cooking methods. In all studies an isocaloric, low AGE diet showed a decrease in serum AGEs and in most studies, except for one⁵³, this decrease is accompanied by a reduction in markers of inflammation and oxidative stress.⁵⁴⁻⁵⁹ In diabetic and obese subjects with insulin resistance, the HOMA-determined insulin sensitivity improved.^{60,61} A calorie-restricted diet reduced plasma AGEs as well, which can be due to a reduced intake of food AGEs or because of other mechanisms such as upregulation of sRAGE or decreased ROS formation.⁶² While AGE lowering diets show a decrease in major serum AGEs the decrease in diabetes patients can be modest: in one study the control group which followed the Standard guideline for good glycemic control actually shows an increase in the major serum AGEs¹²⁷.

Regarding tissue AGE a follow-up study in 2515 participants aged > 55 years showed an increase in SAF of 0.03 for higher dietary CML intake, suggesting that dietary AGEs influence tissue glycation¹²⁸.

It must be noted that AGE intake can largely differ in different populations and countries due to differences in the preparation of food. The effects of a low AGE diet should not be underestimated since the contribution of dietary AGEs is larger than the endogenous amount of formed AGEs in plasma.⁶³

Physical exercise

Physical exercise has shown to be protective against cardiovascular disease, increases longevity and is an important tool to prevent the development of diabetes in subjects with impaired glucose tolerance.⁶⁴ The influence of exercise on AGE levels has been described in several studies.

The first study investigated the effect of short and long runs on changes in methylglyoxal (MG) content in red blood cells of trained and untrained students. Long runs showed to have the largest reduction in MG concentration; 41% and 60% in untrained and trained students respectively.⁶⁵ Another study explored the influence of life-long endurance running on the accumulation of AGEs in connective tissue and found that life-long runners had a 21% lower AGE crosslink density of pentosidine in patellar tendons, accompanied by an 11% decrease in skin AGE levels.⁶⁶ Doing Tai Chi, an exercise of moderate intensity and an aerobic nature, for twelve months, showed a decrease in serum AGEs, most likely by stimulating antioxidant enzymes that reduce oxidative stress.⁶⁷ In addition, a study involving middle-aged females in a 12-week lifestyle modification demonstrated a decrease in serum AGEs, as well as reductions in body fat and serum HDL-cholesterol compared to the control group.⁶⁸

Furthermore, in a 6 months interventional program that was focused on stimulating mild to moderate physical activity in Japanese elderly, a reduction in serum sRAGE was demonstrated. The decrease in sRAGE levels could be explained by a reduction of plasma AGEs, which in its turn can inactivate RAGE expression as well as sRAGE circulation as a scavenger of AGEs.⁶⁹ In contrast, moderate exercise for six months in type 2 diabetic women resulted in increased sRAGE levels and improved cardio-metabolic risk factors. This possibly improves scavenging of AGEs by sRAGE and decreases activation of the AGE-RAGE pathway, preventing cellular dysfunction.⁷⁰ Since these studies show opposing effects, which might be due to the study population, the clinical relevance of the relationship between exercise and sRAGE should be studied further.

Finally, in a 12-week study obese men participated in either a low AGE diet, physical (aerobic) exercise (45 minutes with an intensity of 65-75% of maximum heart rate, three times a week) or a combination of both. In contrast to the other studies, an AGE-reducing effect of performing exercise alone was not perceived. Only in combination with the low AGE diet, this intervention provided a decrease in serum CML and MG.⁷¹

Nutraceuticals

Instead of synthetic pharmaceuticals, compounds from natural sources have attracted attention to inhibit AGEs. Natural AGE inhibitors can be found in vegetables, fruit, tea and medicinal plants and many of them are available as dietary supplements.

Vitamin B and derivatives

It has been reported that diabetic patients have a substantial deficiency of vitamin B1.⁷² Vitamin B6 (pyridoxamine and pyridoxine) and vitamin B1 (thiamine and the synthetic prodrug benfotiamine) supplementation have been described as a potent AGE inhibitory strategy.

Pyridoxamine can inhibit the conversion of Amadori products to AGEs and is able to scavenge reactive oxygen species and the reactive carbonyl intermediates that are products of sugar and lipid degradation.⁷³ Although *in vivo* experiments demonstrated the efficient inhibition of AGEs by pyridoxamine along with positive effects on diabetic nephropathy,⁷⁴ clinical evidence is more ambiguous. In 2007, a phase 2 trial including patients with kidney disease due to type 1 or 2 diabetes, showed the inhibiting effect of pyridoxamine treatment (Pyridorin; NephroGenex, Inc.) on plasma AGEs. Additionally, 6 month pyridoxamine treatment suggested the potential to slow down renal disease by a reduced change in serum creatinine from baseline and urinary TGF β excretion.⁷⁵ In contrast, a second trial in patients with type 2 diabetic nephropathy could not repeat this effect on creatinine, although patients with less renal impairment might profit. It is suggested that the effect of AGE inhibition is more effective in an earlier stage, which may be before the onset of pathologic changes.⁷⁶

The effect of high-dose thiamine (vitamin B1) therapy was examined in a pilot study with type 2 diabetic patients with microalbuminuria and reported decreased urinary albumin excretion after 3 months but no effect on dyslipidaemia, glycaemic control or blood pressure.⁷⁷ Benfotiamine is a prodrug of thiamine with a higher bioavailability, and *in vitro* data indicates that it inhibits three major pathways that elicit hyperglycaemic vascular damage, among which the AGE formation pathway. Benfotiamine is able to inhibit these pathways simultaneously by increasing the activity of the transketolase enzyme. In addition, NF- κ B activation could be prevented by benfotiamine. These effects were able to reduce diabetic retinopathy in an diabetic animal model.⁷⁸ Human studies on benfotiamine are still inconclusive. Studies showing positive results include a beneficial effect on endothelial function, oxidative stress and AGE levels after consumption of a high AGE meal.⁷⁹ Another study reported normalisation of several indicators of hyperglycaemia including AGE formation, although this last study only showed positive effects in combination with alpha-lipoic acid.⁸⁰ Alternatively, Alkhalaf *et al.* concluded in two studies that benfotiamine treatment for 12 weeks did neither reduce urinary albumin excretion (UAE) and excretion of a tubular damage marker, nor did it affect plasma or urinary AGEs and plasma markers of endothelial dysfunction.^{81,82}

Benfotiamine might be profitable for patients with diabetic polyneuropathy. In a double blind, placebo-controlled phase 3 trial, benfotiamine treatment for six weeks improved the Neuropathy Symptom Score (NSS) in the per protocol analysis, with the greatest improvement in the parameter pain.⁸³ Other studies examined the effect of benfotiamine in combination with other B vitamins. A combination of benfotiamine with vitamin B6 and B12 for 12 weeks improved the nerve conduction velocity in the peroneal nerve, and this result was repeated in a 9 month intervention study in 9 patients.⁸⁴ A different study on Milgamma-N (benfotiamine-vitamin B combination) reported therapeutic effects after six weeks on parameters pain and vibration sensation.⁸⁵ However, these results were contradicted in a 24-month study examining the effect of benfotiamine (Benfogamma, Wörwag Pharma) in type 1 diabetic patients without clinical neuropathy. No beneficial effects on peripheral nerve function or inflammatory biomarkers were reported, which might be explained by differences in study population, where an improvement in patients with almost normal nerve function might be unfeasible.⁸⁶

Peptides and amino acids

Peptides and amino acids can counter glycation by reducing blood glucose through binding to the insulin receptor and by neutralizing reactive carbonyls¹²⁵. One of the benefits of bioactive peptides is that they can




Fig. 3 The deleterious effects of AGEs can be stopped by reducing AGE accumulation and decrease RAGE signalling. There are several aspects in the AGE formation pathway that can be targeted by pharmaceutical, lifestyle and nutraceutical interventions.

be synthesized chemically or biosynthetically.

L-carnosine is a naturally occurring dipeptide that is primarily present in the central nervous system and skeletal muscles. *In vitro* studies demonstrated an effective anti-glycosylating effect by reacting with RCS and inhibiting protein crosslinking.⁸⁷ Other protective functions of carnosine are its antioxidant activity by scavenging of reactive oxygen species.⁸⁸

The results obtained from *in vitro* studies make carnosine an interesting potential therapeutic agent. In contrast to rodents, humans possess the carnosinase enzyme, which can degrade carnosine through hydrolysis. Therefore, carnosinase-resistant derivatives such as D-carnosine and its more bioavailable prodrug D-carnosine-octylester (DCO) have been developed. D-carnosine has been proved to have the same efficiency as L-carnosine in quenching RCS and diminishes the development of renal disease and dyslipidaemia in obese Zucker rats.⁸⁹ Moreover, treatment with DCO was able to protect diabetic mice from atherosclerosis and renal disease.^{90,91} Various other *in vivo* studies supported the nephro- and retinoprotective effect of carnosine treatment in diabetic animals.⁹² However, in two of these studies, the protective effects of carnosine could not be explained by the anti-oxidative and anti-glycation characteristics of carnosine, but were exerted through other mechanisms.^{93,94} In clinical studies, carnosine derivative N-acetylcarnosine has been investigated as a treatment for (glycation-induced) cataract. Eyedrops with 1% N-acetylcarnosine (Can-C™ Eye Drops), which is more resistant to carnosinase than L-carnosine, improved vision in both subjects with cataract and without.⁹⁵ The effect of carnosine on the skin has been examined as well, since SAF increases during aging and correlates with AGE deposition in the skin.¹⁰ AGEs induce apoptosis of dermal fibroblasts and crosslinking of collagen, leading to stiffness of the tissue.⁹⁶ The subjects in this study were given supplements that combine L-carnosine with competitive carnosinase inhibitors to increase tissue L-carnosine levels without increasing its concentration in blood plasma (Can-C Plus, Innovative Vision Products, Inc., New Castle, DE, USA). Oral supplementation for three months had a positive influence on signs

of skin aging, such as reduction of fine lines and improved skin appearance.⁹⁷

Supplementation of the amino acid Taurine in a double-blind randomized controlled trial for diabetes patients for 8 weeks shows a significant reduction in serum pentosidine and MGO concentrations and an increase in soluble RAGE.¹²⁶ The anti-glycation activity of Taurine is probably related to its interaction with the insulin receptor. Furthermore, Taurine has anti-oxidant activity and high reactivity against carbonyl compounds.

Polyphenols

Many nutraceuticals are rich in polyphenols that possess anti-glycation activity through various mechanisms, such as regulation of glucose metabolism, antioxidant effects and inhibition of the Aldose Reductase (AR) pathway.⁹⁸ AR is an enzyme in the polyol pathway and active/enhanced under hyperglycaemic conditions. The polyol pathway is an important source of diabetes-induced oxidative stress and the formation of reactive fructose and 3-DG that contribute to AGE accumulation.⁹⁹

Epigallocatechin 3-gallate

Epigallocatechin 3-gallate (EGCG) is the major polyphenol in tea that possesses anti-inflammatory and anti-cancer properties.¹⁰⁰ In a diabetic mouse model, induced by a high fat diet, EGCG proved to decrease AGE accumulation with 80% in kidney and 96% in heart. Furthermore blood glucose levels and weight gain induced by a high-fat diet were reduced and the formation of cataracts could be prevented or delayed.¹⁰¹ In another study mice were treated with low and high doses of EGCG three times a week. After seventeen weeks, mice receiving a high dose of EGCG showed a near reversal of weight gain, improved glucose control and inhibited AGE accumulation in plasma, liver, kidney and adipose tissue.¹⁰² In rats suffering from diabetic nephropathy, EGCG showed comparable results, ameliorating the decline of kidney function.¹⁰³

Additionally, green tea extract that is enriched with EGCG increased sRAGE levels in plasma of T2DM patients. sRAGE acts as a decoy for AGEs, preventing their interaction with RAGE.¹⁰⁴ Simultaneously, EGCG-rich green tea extract decreased RAGE ligand S100A12, which indicates EGCG is able to block RAGE-ligand signalling, and could possibly prevent the progression of inflammatory responses that lead to the complications in diabetes.¹⁰⁵

Although these results suggest the AGE inhibitory potential of the green tea derived EGCG, clinical studies are needed to show whether this could be a useful intervention for the treatment of diabetic complications. Examining the pharmacokinetics and safety issues is of great importance, since the dose used in *in vivo* studies far exceeds the amount of active substance in dietary supplements. Moreover, EGCG has been shown to have a low bioavailability, which led to the design of lipophilized derivatives that demonstrated slightly improved AGE-inhibitory activity *in vitro*.¹⁰⁶

Rutin

Rutin is a dietary flavonoid that is present in fruits, vegetables, tea and wine. Rutin is metabolized to a range of compounds such as quercetin, 3,4-DHT and 3,4-DHPAA. Rutin, along with its metabolites, can inhibit glucose autoxidation, the formation of AGEs and glycation of collagen.¹⁰⁷ Its anti-glycation capacity was again demonstrated on goat eye lens proteins, indicating rutins potential to scavenge free radicals and chelating metal ions. The inhibition of aldose reductase (AR) is another mechanism that explains the benefits of rutin.¹⁰⁸ The lowering effect of rutin on collagen fluorescence in diabetic rats was first described by Odetti *et*

*al.*¹⁰⁹ Further *in vivo* studies demonstrated that G-rutin, a rutin glucose derivative, could reduce glycation of serum and kidney proteins and lipid peroxidation in diabetic rats.¹¹⁰ In addition, rutin had preventive effects on the development of diabetic nephropathy in rats. After 10 weeks not only the expression of AGEs and accumulation of collagen were significantly reduced, fasting glucose levels and oxidative stress were decreased as well. Furthermore, rutin treatment attenuated microalbuminuria and the thickness of the glomerular basement membrane.¹¹¹ Other studies examining the effect of rutin on rats with streptozotocin (STZ)-induced diabetes showed a protective function against kidney damage by positively regulating matrix

remodelling¹¹² and improvement of hyperglycaemia and dyslipidemia, while liver and heart toxicity induced by diabetes were ameliorated.¹¹³ Hence, rutin supplementation might be a potential treatment for diabetic pathological conditions.

Resveratrol

Resveratrol has been described as a polyphenol that possesses anti-oxidant, anti-cancer, anti-inflammation and life extending effects.¹¹⁴ Besides these positive health effects, resveratrol showed the ability to inhibit AGE formation *in vitro*. Resveratrol acted as an inhibitor of α -amylase and α -glucosidase, which are enzymes that catalyse the degradation of carbohydrates.¹¹⁵ Inhibition of these enzymes modulates sugar release and postprandial hyperglycemia and could be used as a therapy to decrease the risk of diabetes complications.¹¹⁶ Two *in vivo* studies report that resveratrol treatment did not affect AGE levels in liver and kidney,

which might be due to relative short exposure time. Nevertheless, resveratrol improved antioxidant status and decreased plasma glucose and RAGE expression in liver and kidney of diabetic rats.^{117,118} Moreover, resveratrol treatment reduces the NF- κ B-RAGE signalling pathway, thereby ameliorating vasculopathy in diabetic rats.¹¹⁹ Furthermore, resveratrol can exert its beneficial effects on diabetic complications by inhibition of Aldose Reductase (AR), resulting in a decrease of AGE formation in the kidney and improvement of the glomerular filtration rate and renal function in diabetic rats. Since AR mediates the polyol levels that contribute to cataract formation, resveratrol is able to inhibit opacification of the lens.¹²⁰ Palsamy *et al.* support that resveratrol is able to normalize AR activity, and additionally other polyol pathway enzymes such as sorbitol dehydrogenase and glyoxalase-I (Glo-I), which limits AGE formation and glycative damage to the kidneys.¹²¹ In a clinical study the effect of resveratrol and hesperetin on vascular function was observed. These dietary bioactive compounds demonstrated to be strong inducers of glyoxalase-I, that is responsible for the detoxification of RCS compound MG. Co-therapy of resveratrol and hesperetin, instead of individual administration, was able to improve fasting plasma glucose, oral glucose insulin sensitivity and arterial and renal function in obese subjects.¹²²

Conclusions

AGEs accumulate in body tissues during one's lifetime and excessive AGE accumulation can induce tissue damage and accelerate aging. The latter is most evident in tissues consisting of long-lived proteins such as the skin, heart, muscles and joints. Furthermore, the glycation reactions and AGEs play a key role in the development and progression of chronic lifestyle-related diseases such as diabetes mellitus, cardiovascular disease and kidney disease. Since SAF measurements represent tissue AGE levels and biological age and are a good independent predictor of the future risk of cardiovascular disease and diabetes, SAF measurements can help promote metabolic and cardiovascular health or aid in the prognosis and treatment options for e.g. diabetic patients. Since AGE accumulation represents glycemic memory interventions against AGEs may well have prolonged positive effects on health. Hence the effectiveness of anti-glycation interventions is of major interest in both promoting health as well as in prevention and treatment of lifestyle conditions.

The complexity of AGE formation and interactions allow for interventions at different levels. The strategies that prevent AGE formation depend on different mechanisms such as antioxidant ability, scavenging of reactive carbonyl species and inhibition of aldose reductase. Pharmaceutical options show promising results, yet their clinical relevance is limited so far due to limited efficacy or safety concerns. For individuals with high AGE levels but no clinical symptoms other interventions might be more effective. Lifestyle interventions such as a low AGE diet and physical exercise are easily to implement and show beneficial effects on plasma AGEs and reduce inflammation and oxidative stress. Nutraceuticals, derived from food sources and available as dietary supplements, have mostly been investigated in pre-clinical studies. Many studies evaluated these compounds as potential anti-glycation therapeutics and showed positive effects on diabetic complications such as nephro- and retinopathy.

References

- Ramasamy, R. *et al.* Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. *Glycobiology* **15**, 16R–28R (2005).
- Ahmed, N. Advanced glycation endproducts--role in pathology of diabetic complications. *Diabetes Res. Clin. Pract.* **67**, 3–21 (2005).
- Baynes, J. W. & Thorpe, S. R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. *Diabetes* **48**, 1–9 (1999).
- Fu, M. X. *et al.* The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. *J. Biol. Chem.* **271**, 9982–9986 (1996).
- Stirban, A., Gawlowski, T. & Roden, M. Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms. *Mol. Metab.* **3**, 94–108 (2014).
- Koschinsky, T. *et al.* Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. *Proc. Natl. Acad. Sci. U. S. A.* **94**, 6474–6479 (1997).
- URIBARRI, J. *et al.* Advanced Glycation End Products in Foods and a Practical Guide to Their Reduction in the Diet. *J. Am. Diet. Assoc.* **110**, 911–16.e12 (2010).
- Cerami, C. *et al.* Tobacco smoke is a source of toxic reactive glycation products. *Proc. Natl. Acad. Sci.* **94**, 13915–13920 (1997).
- Jin, K. Modern Biological Theories of Aging. *Aging Dis.* **1**, 72–74 (2010).
- Corstjens, H. *et al.* Glycation associated skin autofluorescence and skin elasticity are related to chronological age and body mass index of healthy subjects. *Exp. Gerontol.* **43**, 663–667 (2008).
- Xue, M., Rabbani, N. & Thornalley, P. J. Glyoxalase in ageing. *Semin. Cell Dev. Biol.* **22**, 293–301 (2011).
- Bierhaus, A. *et al.* Understanding RAGE, the receptor for advanced glycation end products. *J. Mol. Med. Berl. Ger.* **83**, 876–886 (2005).
- Lander, H. M. *et al.* Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. *J. Biol. Chem.* **272**, 17810–17814 (1997).
- Schmidt, A. M. *et al.* Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. *J. Clin. Invest.* **96**, 1395–1403 (1995).
- Wautier, M. P. *et al.* Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. *Am. J. Physiol. Endocrinol. Metab.* **280**, E685–694 (2001).
- Sims, T. J., Rasmussen, L. M., Oxlund, H. & Bailey, A. J. The role of glycation cross-links in diabetic vascular stiffening. *Diabetologia* **39**, 946–951 (1996).
- Monnier, V. M. *et al.* Cross-Linking of the Extracellular Matrix by the Maillard Reaction in Aging and Diabetes: An Update on ‘a Puzzle Nearing Resolution’. *Ann. N. Y. Acad. Sci.* **1043**, 533–544 (2005).
- McNulty, M., Mahmud, A. & Feely, J. Advanced glycation end-products and arterial stiffness in hypertension. *Am. J. Hypertens.* **20**, 242–247 (2007).
- Beckman, J. A., Creager, M. A. & Libby, P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. *JAMA* **287**, 2570–2581 (2002).
- Vlassara, H. Recent progress in advanced glycation end products and diabetic complications. *Diabetes* **46 Suppl 2**, S19–25 (1997).
- Bucala, R., Tracey, K. J. & Cerami, A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. *J. Clin. Invest.* **87**, 432–438 (1991).
- Frank, R. N. On the pathogenesis of diabetic retinopathy. A 1990 update. *Ophthalmology* **98**, 586–593 (1991).
- Stitt, A. W. The role of advanced glycation in the pathogenesis of diabetic retinopathy. *Exp. Mol. Pathol.* **75**, 95–108 (2003).
- Monnier, V. M. *et al.* Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. *Diabetes* **41 Suppl 2**, 36–41 (1992).
- Yamagishi, S., Fukami, K., Ueda, S. & Okuda, S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. *Curr. Drug Targets* **8**, 952–959 (2007).
- Genuth, S. *et al.* Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. *Diabetes* **54**, 3103–3111 (2005).
- Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R. & Neil, H. A. W. 10-year follow-up of intensive glucose control in type 2 diabetes. *N. Engl. J. Med.* **359**, 1577–1589 (2008).
- Gerrits, E. G. *et al.* Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. *Diabetes Care* **31**, 517–521 (2008).
- Lutgers, H. L. *et al.* Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. *Diabetologia* **52**, 789–797 (2009).
- Thornalley, P. J., Yurek-George, A. & Argirov, O. K. Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. *Biochem. Pharmacol.* **60**, 55–65 (2000).
- Bolton, W. K. *et al.* Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. *Am. J. Nephrol.* **24**, 32–40 (2004).
- Freedman, B. I. *et al.* Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). *Control. Clin. Trials* **20**, 493–510 (1999).
- Kass, D. A. *et al.* Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. *Circulation* **104**, 1464–1470 (2001).
- Zieman, S. J. *et al.* Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. *J. Hypertens.* **25**, 577–583 (2007).
- Little, W. C. *et al.* The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. *J. Card. Fail.* **11**, 191–195 (2005).
- Hartog, J. W. L. *et al.* Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. *Eur. J. Heart Fail.* **13**, 899–908 (2011).

37. Fujimoto, N. *et al.* Cardiovascular effects of 1 year of alagebrium and endurance exercise training in healthy older individuals. *Circ. Heart Fail.* **6**, 1155–1164 (2013).
38. Oudegeest-Sander, M. H. *et al.* The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial. *Exp. Gerontol.* **48**, 1509–1517 (2013).
39. Fang, F. *et al.* RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. *FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.* **24**, 1043–1055 (2010).
40. Galasko, D. *et al.* Clinical trial of an inhibitor of RAGE-A β interactions in Alzheimer disease. *Neurology* **82**, 1536–1542 (2014).
41. Rosen, W. G., Mohs, R. C. & Davis, K. L. A new rating scale for Alzheimer's disease. *Am. J. Psychiatry* **141**, 1356–1364 (1984).
42. Beisswenger, P. J., Howell, S. K., Touchette, A. D., Lal, S. & Szwergold, B. S. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. *Diabetes* **48**, 198–202 (1999).
43. Rabbani, N. *et al.* Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin. *Diabetes* **59**, 1038–1045 (2010).
44. Kimura, Y. *et al.* Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. *J. Gastroenterol.* **45**, 750–757 (2010).
45. Nakamura, T. *et al.* Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs). *Oxid. Med. Cell. Longev.* **3**, 304–307 (2010).
46. Scharnagl, H. *et al.* The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes. *Exp. Clin. Endocrinol. Diabetes Off. J. Ger. Soc. Endocrinol. Ger. Diabetes Assoc.* **115**, 372–375 (2007).
47. Cuccurullo, C. *et al.* Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. *Arterioscler. Thromb. Vasc. Biol.* **26**, 2716–2723 (2006).
48. Sebeková, K. *et al.* Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidative stress and potential modulation of advanced glycation end products. *J. Hum. Hypertens.* **17**, 265–270 (2003).
49. Komiya, N., Hirose, H., Saisho, Y., Saito, I. & Itoh, H. Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension. *Int. Heart. J.* **49**, 681–689 (2008).
50. Ono, Y., Mizuno, K., Takahashi, M., Miura, Y. & Watanabe, T. Suppression of advanced glycation and lipoxidation end products by angiotensin II type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension. *Fukushima J. Med. Sci.* **59**, 69–75 (2013).
51. Saha, S. A., LaSalle, B. K., Clifton, G. D., Short, R. A. & Tuttle, K. R. Modulation of advanced glycation end products by candesartan in patients with diabetic kidney disease--a dose-response relationship study. *Am. J. Ther.* **17**, 553–558 (2010).
52. Engelen, L. *et al.* Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. *Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc.* **26**, 3573–3577 (2011).
53. Semba, R. D. *et al.* Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial. *J. Nutr.* **144**, 1037–1042 (2014).
54. Birlouez-Aragon, I. *et al.* A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. *Am. J. Clin. Nutr.* **91**, 1220–1226 (2010).
55. Luévano-Contreras, C., Garay-Sevilla, M. E., Wrobel, K., Malacara, J. M. & Wrobel, K. Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus. *J. Clin. Biochem. Nutr.* **52**, 22–26 (2013).
56. Macías-Cervantes, M. H. *et al.* Effect of an advanced glycation end product-restricted diet and exercise on metabolic parameters in adult overweight men. *Nutr. Burbank Los Angel. Cty. Calif* **31**, 446–451 (2015).
57. Uribarri, J. *et al.* Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. *J. Am. Soc. Nephrol. JASN* **14**, 728–731 (2003).
58. Vlassara, H. *et al.* Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. *Proc. Natl. Acad. Sci. U. S. A.* **99**, 15596–15601 (2002).
59. Vlassara, H. *et al.* Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. *J. Clin. Endocrinol. Metab.* **94**, 4483–4491 (2009).
60. Mark, A. B. *et al.* Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. *Diabetes Care* **37**, 88–95 (2014).
61. Uribarri, J. *et al.* Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. *Diabetes Care* **34**, 1610–1616 (2011).
62. Gugliucci, A. *et al.* Short-term low calorie diet intervention reduces serum advanced glycation end products in healthy overweight or obese adults. *Ann. Nutr. Metab.* **54**, 197–201 (2009).
63. Henle, T. AGEs in foods: do they play a role in uremia? *Kidney Int. Suppl.* S145-147 (2003). doi:10.1046/j.1523-1755.63.s84.16.x
64. Blair, S. N. & Morris, J. N. Healthy hearts--and the universal benefits of being physically active: physical activity and health. *Ann. Epidemiol.* **19**, 253–256 (2009).
65. Kondoh, Y., Kawase, M. & Ohmori, S. D-lactate concentrations in blood, urine and sweat before and after exercise. *Eur. J. Appl. Physiol.* **65**, 88–93 (1992).
66. Couppé, C. *et al.* Life-long endurance running is associated with reduced glycation and mechanical stress in connective tissue. *Age Dordr. Neth.* **36**, 9665 (2014).
67. Goon, J. A. *et al.* Effect of Tai Chi exercise on DNA damage, antioxidant enzymes, and oxidative stress in middle-age adults. *J. Phys. Act. Health* **6**, 43–54 (2009).
68. Yoshikawa, T., Miyazaki, A. & Fujimoto, S. Decrease in serum levels of advanced glycation end-products by short-term lifestyle modification in non-diabetic middle-aged females. *Med. Sci. Monit. Int. Med. J. Exp. Clin. Res.* **15**, PH65-73 (2009).
69. Kotani, K. *et al.* Influence of Physical Activity Intervention on Circulating Soluble Receptor for Advanced Glycation end Products in Elderly Subjects. *J. Clin. Med. Res.* **3**, 252–257 (2011).

70. Choi, K. M. *et al.* Effects of exercise on sRAGE levels and cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled trial. *J. Clin. Endocrinol. Metab.* **97**, 3751–3758 (2012).
71. Macías-Cervantes, M. H. *et al.* Effect of an advanced glycation end product-restricted diet and exercise on metabolic parameters in adult overweight men. *Nutr. Burbank Los Angel. Cty. Calif* **31**, 446–451 (2015).
72. Thornalley, P. J. *et al.* High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. *Diabetologia* **50**, 2164–2170 (2007).
73. Voziyan, P. A. & Hudson, B. G. Pyridoxamine: the many virtues of a maillard reaction inhibitor. *Ann. N. Y. Acad. Sci.* **1043**, 807–816 (2005).
74. Alderson, N. L. *et al.* The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. *Kidney Int.* **63**, 2123–2133 (2003).
75. Williams, M. E. *et al.* Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. *Am. J. Nephrol.* **27**, 605–614 (2007).
76. Lewis, E. J. *et al.* Pyridorin in type 2 diabetic nephropathy. *J. Am. Soc. Nephrol. JASN* **23**, 131–136 (2012).
77. Rabbani, N. *et al.* High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. *Diabetologia* **52**, 208–212 (2009).
78. Hammes, H.-P. *et al.* Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. *Nat. Med.* **9**, 294–299 (2003).
79. Stirban, A. *et al.* Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. *Diabetes Care* **29**, 2064–2071 (2006).
80. Du, X., Edelstein, D. & Brownlee, M. Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. *Diabetologia* **51**, 1930–1932 (2008).
81. Alkhalaf, A. *et al.* A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. *Diabetes Care* **33**, 1598–1601 (2010).
82. Alkhalaf, A. *et al.* Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. *PLoS One* **7**, e40427 (2012).
83. Stracke, H., Gaus, W., Achenbach, U., Federlin, K. & Bretzel, R. G. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. *Exp. Clin. Endocrinol. Diabetes Off. J. Ger. Soc. Endocrinol. Ger. Diabetes Assoc.* **116**, 600–605 (2008).
84. Stracke, H., Lindemann, A. & Federlin, K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. *Exp. Clin. Endocrinol. Diabetes Off. J. Ger. Soc. Endocrinol. Ger. Diabetes Assoc.* **104**, 311–316 (1996).
85. Winkler, G. *et al.* Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. *Arzneimittelforschung* **49**, 220–224 (1999).
86. Fraser, D. A. *et al.* The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. *Diabetes Care* **35**, 1095–1097 (2012).
87. Hipkiss, A. R. Carnosine, a protective, anti-ageing peptide? *Int. J. Biochem. Cell Biol.* **30**, 863–868 (1998).
88. Boldyrev, A. A. Does carnosine possess direct antioxidant activity? *Int. J. Biochem.* **25**, 1101–1107 (1993).
89. Aldini, G. *et al.* The carbonyl scavenger carnosine ameliorates dyslipidaemia and renal function in Zucker obese rats. *J. Cell. Mol. Med.* **15**, 1339–1354 (2011).
90. Menini, S. *et al.* D-Carnosine octylester attenuates atherosclerosis and renal disease in ApoE null mice fed a Western diet through reduction of carbonyl stress and inflammation. *Br. J. Pharmacol.* **166**, 1344–1356 (2012).
91. Menini, S., Iacobini, C., Ricci, C., Blasetti Fantauzzi, C. & Pugliese, G. Protection from diabetes-induced atherosclerosis and renal disease by D-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in ApoE-null mice. *Diabetologia* **58**, 845–853 (2015).
92. Peters, V. *et al.* Carnosine treatment in combination with ACE inhibition in diabetic rats. *Regul. Pept.* **194–195**, 36–40 (2014).
93. Pfister, F. *et al.* Oral carnosine supplementation prevents vascular damage in experimental diabetic retinopathy. *Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.* **28**, 125–136 (2011).
94. Riedl, E. *et al.* Carnosine prevents apoptosis of glomerular cells and podocyte loss in STZ diabetic rats. *Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.* **28**, 279–288 (2011).
95. Babizhayev, M. A., Micans, P., Guiotto, A. & Kasus-Jacobi, A. N-acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: a clinical study of the new vision-saving drug N-acetylcarnosine eyedrop therapy in a database population of over 50,500 patients. *Am. J. Ther.* **16**, 517–533 (2009).
96. Alikhani, Z. *et al.* Advanced glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways. *J. Biol. Chem.* **280**, 12087–12095 (2005).
97. Babizhayev, M. A., Deyev, A. I., Savel'yeva, E. L., Lankin, V. Z. & Yegorov, Y. E. Skin beautification with oral non-hydrolyzed versions of carnosine and carbinine: Effective therapeutic management and cosmetic skincare solutions against oxidative glycation and free-radical production as a causal mechanism of diabetic complications and skin aging. *J. Dermatol. Treat.* **23**, 345–384 (2012).
98. Khangholi, S., Majid, F. A. A., Berwary, N. J. A., Ahmad, F. & Aziz, R. B. A. The Mechanisms of Inhibition of Advanced Glycation End Products Formation through Polyphenols in Hyperglycemic Condition. *Planta Med.* **82**, 32–45 (2016).
99. Tsukushi, S. *et al.* Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: role of the polyol pathway. *Kidney Int.* **55**, 1970–1976 (1999).
100. Lambert, J. D., Sang, S., Hong, J. & Yang, C. S. Anticancer and Anti-inflammatory Effects of Cysteine Metabolites of the Green Tea Polyphenol, (–)-Epigallocatechin-3-gallate. *J. Agric. Food Chem.* **58**, 10016–10019 (2010).
101. Sampath, C., Sang, S. & Ahmedna, M. In vitro and in vivo inhibition of aldose reductase and advanced glycation end products by phloretin, epigallocatechin 3-gallate and [6]-gingerol. *Biomed. Pharmacother. Biomedicine Pharmacother.* **84**, 502–513 (2016).
102. Sampath, C., Rashid, M. R., Sang, S. & Ahmedna, M. Green tea epigallocatechin 3-gallate alleviates hyperglycemia and reduces advanced glycation end

- products via nrf2 pathway in mice with high fat diet-induced obesity. *Biomed. Pharmacother. Biomedecine Pharmacother.* **87**, 73–81 (2016).
103. Yamabe, N., Yokozawa, T., Oya, T. & Kim, M. Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats. *J. Pharmacol. Exp. Ther.* **319**, 228–236 (2006).
 104. Vazzana, N., Santilli, F., Cucurullo, C. & Davi, G. Soluble forms of RAGE in internal medicine. *Intern. Emerg. Med.* **4**, 389–401 (2009).
 105. Huang, S.-M. *et al.* EGCG-rich green tea extract stimulates sRAGE secretion to inhibit S100A12-RAGE axis through ADAM10-mediated ectodomain shedding of extracellular RAGE in type 2 diabetes. *Mol. Nutr. Food Res.* **57**, 2264–2268 (2013).
 106. Wang, M., Zhang, X., Zhong, Y. J., Perera, N. & Shahidi, F. Antigliation activity of lipophilized epigallocatechin gallate (EGCG) derivatives. *Food Chem.* **190**, 1022–1026 (2016).
 107. Cervantes-Laurean, D. *et al.* Inhibition of advanced glycation end product formation on collagen by rutin and its metabolites. *J. Nutr. Biochem.* **17**, 531–540 (2006).
 108. Muthenna, P., Akileshwari, C., Saraswat, M. & Bhanuprakash Reddy, G. Inhibition of advanced glycation end-product formation on eye lens protein by rutin. *Br. J. Nutr.* **107**, 941–949 (2012).
 109. Odetti, P. R., Borgoglio, A., De Pascale, A., Rolandi, R. & Adezati, L. Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by aminoguanidine and rutin. *Diabetes* **39**, 796–801 (1990).
 110. Nagasawa, T. *et al.* Dietary G-rutin suppresses glycation in tissue proteins of streptozotocin-induced diabetic rats. *Mol. Cell. Biochem.* **252**, 141–147 (2003).
 111. Hao, H. *et al.* Preventive effects of rutin on the development of experimental diabetic nephropathy in rats. *Life Sci.* **91**, 959–967 (2012).
 112. Kamalakkannan, N. & Stanelly Mainzén Prince, P. The influence of rutin on the extracellular matrix in streptozotocin-induced diabetic rat kidney. *J. Pharm. Pharmacol.* **58**, 1091–1098 (2006).
 113. Fernandes, A. A. H. *et al.* Influence of rutin treatment on biochemical alterations in experimental diabetes. *Biomed. Pharmacother. Biomedecine Pharmacother.* **64**, 214–219 (2010).
 114. Yang, T., Wang, L., Zhu, M., Zhang, L. & Yan, L. Properties and molecular mechanisms of resveratrol: a review. *Pharm.* **70**, 501–506 (2015).
 115. Shen, Y., Xu, Z. & Sheng, Z. Ability of resveratrol to inhibit advanced glycation end product formation and carbohydrate-hydrolyzing enzyme activity, and to conjugate methylglyoxal. *Food Chem.* **216**, 153–160 (2017).
 116. Thilagam, E., Parimaladevi, B., Kumarappan, C. & Mandal, S. C. α -Glucosidase and α -amylase inhibitory activity of *Senna surattensis*. *J. Acupunct. Meridian Stud.* **6**, 24–30 (2013).
 117. Khazaei, M. *et al.* Effects of Resveratrol on Receptor for Advanced Glycation End Products (RAGE) Expression and Oxidative Stress in the Liver of Rats with Type 2 Diabetes. *Phytother. Res. PTR* **30**, 66–71 (2016).
 118. Moridi, H. *et al.* Resveratrol-Dependent Down-regulation of Receptor for Advanced Glycation End-products and Oxidative Stress in Kidney of Rats With Diabetes. *Int. J. Endocrinol. Metab.* **13**, e23542 (2015).
 119. Jing, Y.-H., Chen, K.-H., Yang, S.-H., Kuo, P.-C. & Chen, J.-K. Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: role of AGE-RAGE signalling. *Diabetes Metab. Res. Rev.* **26**, 212–222 (2010).
 120. Ciddi, V. & Dodda, D. Therapeutic potential of resveratrol in diabetic complications: In vitro and in vivo studies. *Pharmacol. Rep. PR* **66**, 799–803 (2014).
 121. Palsamy, P. & Subramanian, S. Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. *Biochim. Biophys. Acta* **1812**, 719–731 (2011).
 122. Xue, M. *et al.* Improved Glycemic Control and Vascular Function in Overweight and Obese Subjects by Glyoxalase 1 Inducer Formulation. *Diabetes* **65**, 2282–2294 (2016).
 123. C. Nigro *et al.* Dicarbonyl Stress at the Crossroads of Healthy and Unhealthy Aging. *Cells* **8** 749 (2018)
 124. Ojima *et al.* Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis Horm Metab Res 47: 686–692 (2015)
 125. H. Chilukuri Revisiting amino acids and peptides as antiglycation agents Med. Chem. Commun. 9, 614 (2018)
 126. F. Esmaili *et al.* The Effects of Taurine Supplementation on Metabolic Profiles, Pentosidine, Soluble Receptor of Advanced Glycation End Products and Methylglyoxal in Adults With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. *CJD* **45** 1 (2020)
 127. R. Lotan *et al.* Long Term Dietary Restriction of Advanced Glycation End-Products (AGEs) in Older Adults with Type 2 Diabetes Is Feasible and Efficacious-Results from a Pilot RCT Nutrients **12** 3143 (2020)
 128. J. Chen *et al.* The association between dietary and skin advanced glycation end products: the Rotterdam Study Am J Clin Nutr **112** 129 (2020)